Paclitaxel Injection Market by Treatment of Various Cancers - Global Industry Analysis and Forecast to 2023
Published On : March 2018 Pages : 80 Category: Healthcare IT Report Code : HC03665
Industry Outlook and Trend Analysis
The Paclitaxel Injection Market was has encountered significant development in the recent years and is anticipated to grow tremendously in the following years. Paclitaxel belongs to the section of medicines recognised as antineoplastics and is used as in the treatment of cancers. It works by hindering the development of cancer cells and is used in the treatment of different cancers, for example, ovarian cancer, non-small cell lung cancer, breast cancer, and so on. As indicated by the WHO, cancer was the main source of death around the world, representing the death of 8.2 million individuals in 2017. The real drivers for this market are the rising rate of cancer universally and the enhanced adequacy of paclitaxel injections. Nonetheless, unfavourable reactions related with the medication and in addition the development of targeted treatment, customized medicine and novel anti-cancer drugs would be a challenge to the development of this market.
Treatment of Various Cancers Outlook and Trend Analysis
Paclitaxel Injection is used in the treatment of ovarian cancer, Breast cancer, Non-small cell lung cancer, Cervical Cancer, AIDS related Kaposi's sarcoma, Prostate cancer, Esophageal cancer, Stomach cancer, Testicular cancer, Pancreatic cancer, Lung cancer and Others. As per the WHO, stomach cancer represented 723,000 deaths and breast cancer represented 521,000 deaths separately in the year 2017 alone. Paclitaxel is made use of for the treatment of both these cancers and the rising occurrences of disease would bring about expanded usage of this medication for treatment.
Regional Outlook and Trend Analysis
Geographically, the market is ruled by North America owing to the high incidence of Cancer patients in this region. However, Europe and Asia Pacific are developing markets owing to rising incidences of cancer.
Competitive Insights
The leading players in the market are Sagent Pharmaceuticals, Abbott Laboratories, Abraxis BioScience, Fresenius Kabi Oncology Ltd, Novasep Inc, Onco therapies Ltd and Celgene. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The Paclitaxel Injection Market is segmented as follows-
By use in treatment of various cancers:
- Ovarian cancer
- AIDS related Kaposi's sarcoma
- Esophageal cancer
- Stomach cancer
- Lung cancer
- Breast cancer
- Non-small cell lung cancer
- Cervical Cancer
- Prostate cancer
- Testicular cancer
- Pancreatic cancer
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2023?
- What will be the industry market growth from 2017 to 2023?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Paclitaxel Injection Market, By Treatment of Various Cancers, Estimates and Forecast, 2014-2023($Million)
· Breast cancer
· Ovarian cancer
· Non -small cell lung cancer
· AIDS related Kaposi's sarcoma
· Cervical Cancer
· Esophageal cancer
· Prostate cancer
· Stomach cancer
· Testicular cancer
· Lung cancer
· Pancreatic cancer
· Other Treatment of Various Cancers
· Paclitaxel Injection Market, By Region, Estimates and Forecast, 2014-2023($Million)
o North America
§ North America Paclitaxel Injection Market, By Country
o U.S. Paclitaxel Injection Market
o Canada Paclitaxel Injection Market
o Mexico Paclitaxel Injection Market
o Europe
§ Europe Paclitaxel Injection Market, By Country
o Germany Paclitaxel Injection Market
o UK Paclitaxel Injection Market
o France Paclitaxel Injection Market
o Russia Paclitaxel Injection Market
o Italy Paclitaxel Injection Market
o Rest of Europe Paclitaxel Injection Market
o Asia-Pacific
§ Asia-Pacific Paclitaxel Injection Market, By Country
o China Paclitaxel Injection Market
o Japan Paclitaxel Injection Market
o South Korea Paclitaxel Injection Market
o India Paclitaxel Injection Market
o Southeast Asia Paclitaxel Injection Market
o Rest of Asia-Pacific Paclitaxel Injection Market
o South America
§ South America Paclitaxel Injection Market
o Brazil Paclitaxel Injection Market
o Argentina Paclitaxel Injection Market
o Columbia Paclitaxel Injection Market
o South Africa Paclitaxel Injection Market
o Rest of South America Paclitaxel Injection Market
o Middle East and Africa
§ Middle East and Africa Paclitaxel Injection Market
o Saudi Arabia Paclitaxel Injection Market
o UAE Paclitaxel Injection Market
o Egypt Paclitaxel Injection Market
o Nigeria Paclitaxel Injection Market
o South Africa Paclitaxel Injection Market
o Rest of MEA Paclitaxel Injection Market
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rising Demand in End-User Industries
3.2.2. Restraints
3.2.2.1. Volatile Raw Material Prices
3.2.3. Opportunities
3.2.3.1. Emerging Countries to Offer Lucrative Growth Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2023)
4.1.2. Canada Market States and Outlook (2017-2023)
4.1.3. Mexico Market States and Outlook (2017-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2023)
4.2.2. France Market States and Outlook (2017-2023)
4.2.3. UK Market States and Outlook (2017-2023)
4.2.4. Russia Market States and Outlook (2017-2023)
4.2.5. Italy Market States and Outlook (2017-2023)
4.2.6. Rest of Europe Market States and Outlook (2017-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2023)
4.3.2. Japan Market States and Outlook (2017-2023)
4.3.3. Korea Market States and Outlook (2017-2023)
4.3.4. India Market States and Outlook (2017-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2017-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2023)
4.4.2. Argentina Market States and Outlook (2017-2023)
4.4.3. Columbia Market States and Outlook (2017-2023)
4.4.4. Rest of South America Market States and Outlook (2017-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2023)
4.5.2. UAE Market States and Outlook (2017-2023)
4.5.3. Egypt Market States and Outlook (2017-2023)
4.5.4. Nigeria Market States and Outlook (2017-2023)
4.5.5. South Africa Market States and Outlook (2017-2023)
4.5.6. Rest of MEA Market States and Outlook (2017-2023)
5. Paclitaxel Injection Market, By Treatment of Various Cancers
5.1. Introduction
5.2. Global Paclitaxel Injection Sales, Revenue and Market Share by Treatment of Various Cancers (2017-2027)
5.2.1. Global Paclitaxel Injection Sales and Sales Share by Treatment of Various Cancers (2017-2027)
5.2.2. Global Paclitaxel Injection Revenue and Revenue Share by Treatment of Various Cancers (2017-2027)
5.3. Breast Cancer
5.3.1. Global Breast Cancer Sales and Growth Rate (2017-2027)
5.4. Ovarian Cancer
5.4.1. Global Ovarian Cancer Sales and Growth Rate (2017-2027)
5.5. Non-Small Cell Lung Cancer
5.5.1. Global Non-Small Cell Lung Cancer Sales and Growth Rate (2017-2027)
5.6. AIDS Related Kaposi's Sarcoma
5.6.1. Global AIDS Related Kaposi's Sarcoma Sales and Growth Rate (2017-2027)
5.7. Cervical Cancer
5.7.1. Global Cervical Cancer Sales and Growth Rate (2017-2027)
5.8. Esophageal Cancer
5.8.1. Global Esophageal Cancer Sales and Growth Rate (2017-2027)
5.9. Prostate Cancer
5.9.1. Global Prostate Cancer Sales and Growth Rate (2017-2027)
5.10. Stomach Cancer
5.10.1. Global Stomach Cancer Sales and Growth Rate (2017-2027)
5.11. Testicular Cancer
5.11.1. Global Testicular Cancer Sales and Growth Rate (2017-2027)
5.12. Lung Cancer
5.12.1. Global Lung Cancer Sales and Growth Rate (2017-2027)
5.13. Pancreatic cancer
5.13.1. Global Pancreatic cancer Sales and Growth Rate (2017-2027)
5.14. Other Treatments of Various Cancer
5.14.1. Global Other Treatments of Various Cancer Sales and Growth Rate (2017-2027)
6. Paclitaxel Injection Market, By Region
6.1. Introduction
6.2. Global Paclitaxel Injection Sales, Revenue and Market Share by Regions
6.2.1. Global Paclitaxel Injection Sales by Regions (2017-2027)
6.2.2. Global Paclitaxel Injection Revenue by Regions (2017-2027)
6.3. North America Paclitaxel Injection by Countries
6.3.1. North America Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.3.2. North America Paclitaxel Injection Revenue and Growth Rate (2017-2027)
6.3.3. North America Paclitaxel Injection Sales by Countries (2017-2027)
6.3.4. North America Paclitaxel Injection Revenue (Million USD) by Countries (2017-2027)
6.3.5. U.S.
6.3.5.1. United States Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.3.5.2. United States Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.6. Canada
6.3.6.1. Canada Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.3.6.2. Canada Paclitaxel Injection Sales (Millions USD) and Growth Rate (2017-2027)
6.3.7. Mexico
6.3.7.1. Mexico Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.3.7.2. Mexico Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Paclitaxel Injection by Countries
6.4.1. Europe Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.2. Europe Paclitaxel Injection Revenue and Growth Rate (2017-2027)
6.4.3. Europe Paclitaxel Injection Sales by Countries (2017-2027)
6.4.4. Europe Paclitaxel Injection Revenue (Million USD) by Countries (2017-2027)
6.4.5. Germany
6.4.5.1. Germany Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.5.2. Germany Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. UK
6.4.6.1. UK Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.6.2. UK Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. France
6.4.7.1. France Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.7.2. France Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Russia
6.4.8.1. Russia Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.8.2. Russia Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.9. Italy
6.4.9.1. Italy Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.9.2. Italy Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.10. Rest of Europe
6.4.10.1. Rest of Europe Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.4.10.2. Rest of Europe Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific
6.5.1. Asia-Pacific Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Paclitaxel Injection Revenue and Growth Rate (2017-2027)
6.5.3. Asia-Pacific Paclitaxel Injection Sales by Countries (2017-2027)
6.5.4. Asia-Pacific Paclitaxel Injection Revenue (Million USD) by Countries (2017-2027)
6.5.5. China
6.5.5.1. China Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.5.2. China Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. Japan
6.5.6.1. Japan Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.6.2. Japan Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6.3.
6.5.7. Korea
6.5.7.1. Korea Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.7.2. Korea Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. India
6.5.8.1. India Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.8.2. India Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.9. Southeast Asia
6.5.9.1. Southeast Asia Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.9.2. Southeast Asia Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.10. Rest of Asia-Pacific
6.5.10.1. Rest of Asia-Pacific Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.5.10.2. Rest of Asia-Pacific Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America
6.6.1. South America Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.6.2. South America Paclitaxel Injection Revenue and Growth Rate (2017-2027)
6.6.3. South America Paclitaxel Injection Sales by Countries (2017-2027)
6.6.4. South America Paclitaxel Injection Revenue (Million USD) by Countries (2017-2027)
6.6.5. Brazil
6.6.5.1. Brazil Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.6.5.2. Brazil Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Argentina
6.6.6.1. Argentina Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.6.6.2. Argentina Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.7. Columbia
6.6.7.1. Columbia Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.6.7.2. Columbia Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.8. Rest of South America
6.6.8.1. Rest of South America Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.6.8.2. Rest of South America Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa
6.7.1. Middle East and Africa Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Paclitaxel Injection Revenue and Growth Rate (2017-2027)
6.7.3. Middle East and Africa Paclitaxel Injection Sales by Countries (2017-2027)
6.7.4. Middle East and Africa Paclitaxel Injection Revenue (Million USD) by Countries (2017-2027)
6.7.5. Saudi Arabia
6.7.5.1. Saudi Arabia Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.5.2. Saudi Arabia Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. United Arab Emirates
6.7.6.1. United Arab Emirates Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.6.2. United Arab Emirates Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. Egypt
6.7.7.1. Egypt Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.7.2. Egypt Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Nigeria
6.7.8.1. Nigeria Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.8.2. Nigeria Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. South Africa
6.7.9.1. South Africa Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.9.2. South Africa Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.10. Rest of Middle East and Africa
6.7.10.1. Rest of Middle East and Africa Paclitaxel Injection Sales and Growth Rate (2017-2027)
6.7.10.2. Rest of Middle East and Africa Paclitaxel Injection Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Abraxis Bio Science Inc.
7.1.1. Business Overview
7.1.2. Product Portfolio
7.1.3. Strategic Developments
7.1.4. Sales, Revenue and Market Share
7.2. Celgene
7.2.1. Business Overview
7.2.2. Product Portfolio
7.2.3. Strategic Developments
7.2.4. Sales, Revenue and Market Share
7.3. Abbott Laboratories
7.3.1. Business Overview
7.3.2. Product Portfolio
7.3.3. Strategic Developments
7.3.4. Sales, Revenue and Market Share
7.4. Fresenius Kabi Oncology Ltd
7.4.1. Business Overview
7.4.2. Product Portfolio
7.4.3. Strategic Developments
7.4.4. Sales, Revenue and Market Share
7.5. Onco therapies Ltd
7.5.1. Business Overview
7.5.2. Product Portfolio
7.5.3. Strategic Developments
7.5.4. Sales, Revenue and Market Share
7.6. Novasep
7.6.1. Business Overview
7.6.2. Product Portfolio
7.6.3. Strategic Developments
7.6.4. Sales, Revenue and Market Share
7.7. Sagent Pharmaceuticals
7.7.1. Business Overview
7.7.2. Product Portfolio
7.7.3. Strategic Developments
7.7.4. Sales, Revenue and Market Share
7.8. Youcare Pharmaceutical Group Co., Ltd
7.8.1. Business Overview
7.8.2. Product Portfolio
7.8.3. Strategic Developments
7.8.4. Sales, Revenue and Market Share
7.9. BEIJING Union Pharmaceutical Factory
7.9.1. Business Overview
7.9.2. Product Portfolio
7.9.3. Strategic Developments
7.9.4. Sales, Revenue and Market Share
7.10. Bristol-Myers Squibb Company
7.10.1. Business Overview
7.10.2. Product Portfolio
7.10.3. Strategic Developments
7.10.4. Sales, Revenue and Market Share
8. Global Paclitaxel Injection Market Competition, by Manufacturer
8.1. Global Paclitaxel Injection Sales and Market Share by Manufacturer (2017-2017)
8.2. Global Paclitaxel Injection Revenue and Market Share by Manufacturer (2017-2017)
8.3. Global Paclitaxel Injection Price by Manufacturer (2017-2017)
8.4. Top 5 Paclitaxel Injection Manufacturer Market Share
8.5. Market Competition Trend
9. Paclitaxel Injection Market Forecast (2027-2023)
9.1. Global Paclitaxel Injection Sales, Revenue (Millions USD) and Growth Rate (2027-2023)
9.2. Paclitaxel Injection Market Forecast by Regions (2027-2023)
9.2.1. North America Paclitaxel Injection Market Forecast (2027-2023)
9.2.1.1. United States Paclitaxel Injection Market Forecast (2027-2023)
9.2.1.2. Canada Paclitaxel Injection Market Forecast (2027-2023)
9.2.1.3. Mexico Paclitaxel Injection Market Forecast (2027-2023)
9.2.2. Europe Paclitaxel Injection Market Forecast (2027-2023)
9.2.2.1. Germany Paclitaxel Injection Market Forecast (2027-2023)
9.2.2.2. United Kingdom Paclitaxel Injections Market Forecast (2027-2023)
9.2.2.3. France Paclitaxel Injection Market Forecast (2027-2023)
9.2.2.4. Russia Paclitaxel Injection Market Forecast (2027-2023)
9.2.2.5. Italy Paclitaxel Injection Market Forecast (2027-2023)
9.2.2.6. Rest of the Europe Paclitaxel Injection Market Forecast (2027-2023)
9.2.3. Asia-Pacific Paclitaxel Injection Market Forecast (2027-2023)
9.2.3.1. China Paclitaxel Injection Market Forecast (2027-2023)
9.2.3.2. Japan Paclitaxel Injection Market Forecast (2027-2023)
9.2.3.3. Korea Paclitaxel Injection Market Forecast (2027-2023)
9.2.3.4. India Paclitaxel Injection Market Forecast (2027-2023)
9.2.3.5. Southeast Asia Paclitaxel Injection Market Forecast (2027-2023)
9.2.3.6. Rest of Asia-Pacific Paclitaxel Injection Market Forecast (2027-2023)
9.2.4. South America Paclitaxel Injection Market Forecast (2027-2023)
9.2.4.1. Brazil Paclitaxel Injection Market Forecast (2027-2023)
9.2.4.2. Argentina Paclitaxel Injection Market Forecast (2027-2023)
9.2.4.3. Columbia Paclitaxel Injection Market Forecast (2027-2023)
9.2.4.4. Rest of South America Paclitaxel Injection Market Forecast (2027-2023)
9.2.5. Middle East and Africa Paclitaxel Injection Market Forecast (2027-2023)
9.2.5.1. Saudi Arabia Paclitaxel Injection Market Forecast (2027-2023)
9.2.5.2. UAE Paclitaxel Injection Market Forecast (2027-2023)
9.2.5.3. Egypt Paclitaxel Injection Market Forecast (2027-2023)
9.2.5.4. Nigeria Paclitaxel Injection Market Forecast (2027-2023)
9.2.5.5. South Africa Paclitaxel Injection Market Forecast (2027-2023)
9.2.5.6. Rest of MEA Paclitaxel Injection Market Forecast (2027-2023)
9.3. Paclitaxel Injection Market Forecast by Treatment of Various Cancers (2027-2023)
9.3.1. Global Paclitaxel Injection Sales Forecast by Treatment of Various Cancers (2027-2023)
9.3.2. Global Paclitaxel Injection Sales Market Share Forecast by Treatment of Various Cancers (2027-2023)
List of Tables
*You can glance through the list of Tables and Figures when you view the sample copy of Paclitaxel Injection Market.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|